Author:
Kibirige Davis,Sekitoleko Isaac,Lumu William,Nyirenda Moffat J.
Abstract
Abstract
Background
The rate of progression of type 2 diabetes following diagnosis varies across individuals and populations. Studies investigating the progression of type 2 diabetes in adult African populations with newly diagnosed diabetes are limited. We aimed to investigate the prevalence and predictors of short-term (one year) diabetes progression in an adult Ugandan population with new-onset type 2 diabetes (type 2 diabetes diagnosed in < 3 months) initiated on oral hypoglycaemic agents (OHA).
Methods
Two hundred and seven adult participants with type 2 diabetes diagnosed within the previous three months were followed up for 12 months. We investigated the association of specific demographic, clinical, and metabolic characteristics, and short-term diabetes progression (defined as glycated haemoglobin or HbA1c ≥ 8% on ≥ 2 OHA and/or treatment intensification).
Results
One hundred sixteen participants (56%) completed the follow-up period. Sixty-four participants (55.2%, 95% CI 45.7–64.4) showed evidence of diabetes progression during the 12-month period of follow-up. An HbA1c ≥ 8% on ≥ 2 OHA and treatment intensification were noted in 44.8% and 29.3% of the participants, respectively. On multivariate analysis, only the female gender (AOR 3.2, 95% CI 1.1–9.2, p = 0.03) was noted to be independently associated with short-term diabetes progression.
Conclusion
Short-term diabetes progression was relatively common in this study population and was independently associated with the female gender. Early intensified diabetes therapy in adult Ugandan female patients with new-onset type 2 diabetes should be emphasised to avert rapid short-term diabetes progression.
Funder
UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement
National Institute for Health Research (NIHR) Global Health Research Grant
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Pearson ER. Type 2 diabetes: a multifaceted disease. Diabetologia. 2019;62:1107–12.
2. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S151–6.
3. Kalra S, Kamaruddin NA, Visvanathan J, Santani R. Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus. Eur Endocrinol. 2019;15:67–9.
4. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998;15:290–6.
5. Liu S, Liu JJ, Gurung RL, Chan C, Yeo D, Ang K, et al. Clinical determinants of diabetes progression in multiethnic Asians with type 2 diabetes - a 3-year prospective cohort study. Ann Acad Med Singap. 2019;48:217–23.